Jose Leonel Ochoa-Bayona MD

Assistant Professor, Oncologic Sciences, USF-Morsani

177 La Casa ViaSte 390Walnut Creek, CA 94598
Phone+1 925-677-5041
Fax+1 813-745-8468

Dr. Ochoa-Bayona is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ochoa-Bayona's full profile Already have an account?

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1998 - 2001
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Internal Medicine, 1995 - 1998
Universidad Autonoma de Nuevo LeonClass of 1989

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2021 - 2027
FL State Medical License 2007 - 2027
TX State Medical License 2003 - 2026
PR State Medical License 2012 - 2022
LA State Medical License 2001 - 2002
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2016-2017
CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2016-2017
CMS Meaningful Use Stage 1 Certification HealtheLife and PowerChart, Cerner Corporation, 2016-2017

Clinical Trials

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma Start of enrollment: 2009 Jun 18
Completed
Phase 2
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease Start of enrollment: 2012 Nov 14
Completed
Phase 1, Phase 2
Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease Start of enrollment: 2014 Oct 29
Completed
Phase 1

Publications & Presentations

PubMed

1 citations
Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide.
Jena Schmitz, Eric Gaskill, Samantha Price, Biwei Cao, Jongphil Kim
Bone Marrow Transplantation. 2025-10-01
Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning With Haploidentical Donor Peripheral Blood Stem Cell Transplant.
Hany Elmariah, Jongphil Kim, Rebecca Gonzalez, Elizabeth DiMaggio, Samer Sansil
American Journal of Hematology. 2025-09-01
1 citations
Enhanced CAR-T cell function and mitochondrial fitness from earlier unfractionated stem cell product in multiple myeloma.
Ciara L Freeman, Julieta Abraham-Miranda, Meghan Menges, Reginald M Atkins, Jerald Noble
Molecular Therapy. 2025-08-06

Abstracts/Posters

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Omar Alexis Castaneda Puglianini, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis...
Omar Alexis Castaneda Puglianini, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma
Omar Alexis Castaneda Puglianini, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019